Treatment for diabetic mononeuropathy with α-lipoic acid

International Journal of Clinical Practice

Volumn 59, Issue 6, 2005, Pages 645-650

  Tankova, Tsvetalina ^a   Cherninkova, S ^a   Koev, D ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

lipoic acid; Diabetic mononeuropathy; Mononeuropathia multiplex; Ocular cranial nerves

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; THIOCTIC ACID; ANTIOXIDANT;

ABDUCENS NERVE PARALYSIS; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NEUROPATHY; DIABETIC NEUROPATHY; DIPLOPIA; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EYE MOVEMENT; FEMALE; FOOT PAIN; GLYCEMIC CONTROL; HUMAN; HYPERPNEA; INSULIN DEPENDENT DIABETES MELLITUS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; METATARSAL BONE; MONONEUROPATHY MULTIPLEX; MYDRIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PERCEPTIVE THRESHOLD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PTOSIS; SCORING SYSTEM; STUDENT T TEST; TOE; TREATMENT OUTCOME; TROCHLEAR NERVE DISEASE; UPPER EYELID; VALSALVA MANEUVER; VIBRATION SENSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIOXIDANTS; CRANIAL NERVE DISEASES; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; THIOCTIC ACID;

EID: 23844528541     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00452.x     Document Type: Article

References (29)

1. Coppini DV, Bowtell PA, Weng C et al. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-23.
2. Boulton AJM. New treatments for diabetic neuropathy. Curr Opin Endocrinol Diabet 1996; 3: 330-4.
3. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-73. 10.1007/s001250051477
4. Dam SVP, Sweder VAP, Erkelens DW et al. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995; 11: 181-92.
5. Hermann R, Gleiter GH, Niebch G et al. liponsaure (Thioctsaure) -aktueller stand zur enantioselektiven pharmakokinetik bei gesunden und diabetikern. Diabet Stoffwechsel 1996; 5: 5-11.
6. Merz PG, Rietbrock S, Schrodter A et al. Orales -liponsaurepraparat erweist gute bioverfugbarkeit. Therapie Woche 1995; 23: 1367-70.
7. Packer L, Witt E, Tritschler H. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 2: 227-50. 10.1016/ 0891-5849(95)00017-R
8. Peter G, Borbe HO. Untersuchungen zur absorption und verteilung der thioctsaure als grundlage der klinischen wirksamkeit bei der behandlung der diabetischen polyneuropathie. Diabet Stoffwechsel 1996; 5: 12-6.
9. Nagamatsu M, Nickander KK, Schmeizer J et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-7.
10. Ziegler D, Hanefeld M, Ruhnau KJ et al. and the ALADIN Study Group. Treatament of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. Diabetologia 1995; 38: 1425-33. 10.1007/ BF00400603
11. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effect of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized, controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-73.
12. Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic peripheral neuropathy with the antioxidant thioctic acid (α-lipoic acid). A two-year multicenter randomized double blind placebo-controlled trial (ALADIN II). Free Radic Res 1999; 31: 171-9.
13. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999; 22: 1296-301.
14. Ruhnau KJ, Meissner HP, Finn JR et al. Effect of a 3-week oral treatment with the antioxidant thioctic acid (α-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999; 16: 1040-3. 10.1046/ j.1464-5491.1999.00190.x
15. Ametov A, Barinov A, Dyck PJ et al. and the SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial. Diabetes Care 2003; 26: 770-6.
16. Ziegler D, Nowak H, Kempler P et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A meta-analysis. Diabet Med 2004; 21: 114-21. 10.1111/j.1464-5491.2004.01109.x
17. Tankova T, Koev D, Dakovska L. α-lipoic acid in the treatment of severe diabetic neuropathy (controlled, randomized, open-labelled trial). Jurnalul Roman de Diabet Nutritie si Boli Metabolice 2000; 8: 17-21.
18. Ewing DJ, Marty C, Young R, Clarke B. The value of cardiovascular function tests: 10 years experiences in diabetes. Diabetes Care 1985; 8: 491-8.
19. Jermendy G, Kempler P, Kerenyi Z et al. Clinical features, diagnosis and therapy of autonomic neuropathy. In: Kempler P, Ed. Neuropathies - Nerve Dysfuntion of Diabetic and Other Origin. New York: Springer Verlag, 1997; 86-91
20. Watanabe K, Hagura R, Akanuma Y et al. Characteristics of cranial nerve palsies in diabetic patients. Diabetes Res Clin Pract 1990; 10: 19-27.
21. El Mansouri Y, Bentahar H, Laouissi N et al. Acquired oculomotor paralysis: A new therapeutic approach. Apropos of 10 cases. J Fr Ophthalmol 2000; 23: 225-8.
22. Lazzaroni F, Laffi GL, Galuppi V et al. Paralysis of oculomotor nerves in diabetes mellitus. A retrospective study of 44 cases. Rev Neurol 1993; 149: 571-3.
23. Naghmi R, Subuhi R. Diabetic oculomotor mononeuropathy: Involvement of pupillomotor fibres with slow resolution. Horm Metab Res 1990; 22: 38-40.
24. Berlit P. Isolated and combined pareses of cranial nerves III, IV and VI. A retrospective study of 412 patients. J Neurol Sci 1991; 103: 10-15.
25. Shimizu H, Shimomura Y, Inukai T et al. Immediate improvement of diabetic mononeuropathy after intravenous administration of prostaglandin E1. Jpn J Med 1990; 29: 222-5.
26. Kubatko-Zielinska A, Krzystkowa KM, Madroszkiewicz A et al. Principles and results of treatment in acquired paralysis of III, IV and VI nerves. Klin Oczna 1995; 97: 147-51.
27. Fraser DM, Campbell IW, Ewing DJ et al. Mononeuropathy in diabetes mellitus. Diabetes 1979; 28: 96-101.
28. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-8.
29. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.